Background The myelodysplastic syndromes and myeloproliferative disorders are associated
with deregulated production of myeloid cells. The mechanisms underlying these disorders …

Blood myeloid cells are known to be dysregulated in coronavirus disease 2019 (COVID-19),
caused by SARS-CoV-2. It is unknown whether the innate myeloid response differs with …

Background Risk stratification and therapeutic decision-making for myelodysplastic
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), …

Purpose Several prognostic scoring systems have been proposed for chronic myelomonocytic
leukemia (CMML), a disease in which some gene mutations—including ASXL1—have …

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer 1 , 2 . In patients with
myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease …

Oncogenic pathways underlying in the development of myelodysplastic syndromes (MDS)
remain poorly characterized, but mutations of the ten-eleven translocation 2 (TET2) gene are …

Genomic studies in chronic myeloid malignancies, including myeloproliferative neoplasms (MPN),
myelodysplastic syndromes (MDS), and MPN/MDS, have identified common …

A cohort of MDS patients was examined for mutations affecting 4 splice genes (SF3B1,
SRSF2, ZRSR2, and U2AF35) and evaluated in the context of clinical and molecular markers. …

Cancer cells require nutrients and energy to adapt to increased biosynthetic activity, and
protein synthesis inhibition downstream of mammalian target of rapamycin complex 1 (mTORC1…

Background Acquired somatic deletions and loss-of-function mutations in one or several
codons of the TET2 (Ten-Eleven Translocation-2) gene were recently identified in …